Afya Limited (NASDAQ:AFYA) Stock Has Average Target Price of $17.25 According to Analysts

by · The Markets Daily

Shares of Afya Limited (NASDAQ:AFYA – Get Free Report) have been assigned an average recommendation of “Hold” from the seven research firms that are currently covering the stock, Marketbeat.com reports. Five equities research analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $17.25.

Several research analysts recently issued reports on AFYA shares. Wall Street Zen raised shares of Afya from a “hold” rating to a “buy” rating in a research report on Saturday, September 5th. Bradesco Corretora raised Afya to an “outperform” rating and set a $17.00 target price for the company in a report on Thursday, September 24th. Zacks Research upgraded Afya from a “strong sell” rating to a “hold” rating in a research report on Monday, October 5th. Weiss Ratings lowered Afya from a “hold (c)” rating to a “hold (c-)” rating in a research note on Friday, July 31st. Finally, JPMorgan Chase & Co. raised Afya from a “neutral” rating to an “overweight” rating and cut their price objective for the company from $21.00 to $19.00 in a report on Wednesday, October 7th.

View Our Latest Analysis on AFYA

Insider Activity

In related news, insider Santos Welder Ferreira sold 4,161 shares of the stock in a transaction dated Monday, October 5th. The shares were sold at an average price of $13.30, for a total transaction of $55,341.30. Following the completion of the sale, the insider owned 35,000 shares in the company, valued at $465,500. This trade represents a 10.63% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 0.80% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in Afya stock. Engineers Gate Manager LP acquired a new position in Afya Limited (NASDAQ:AFYA – Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 21,882 shares of the company’s stock, valued at approximately $325,000. 88.02% of the stock is currently owned by institutional investors.

Afya Trading Up 0.1%

Shares of Afya stock opened at $14.91 on Tuesday. The firm has a market capitalization of $1.40 billion, a PE ratio of 8.47, a price-to-earnings-growth ratio of 1.81 and a beta of 0.34. The company has a debt-to-equity ratio of 0.39, a current ratio of 2.20 and a quick ratio of 2.20. The company’s fifty day moving average price is $13.95 and its two-hundred day moving average price is $14.23. Afya has a 52-week low of $11.62 and a 52-week high of $16.16.

Afya (NASDAQ:AFYA – Get Free Report) last announced its quarterly earnings data on Friday, August 14th. The company reported $0.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.40 by $0.03. Afya had a net margin of 20.55% and a return on equity of 17.58%. The company had revenue of $187.80 million during the quarter, compared to analysts’ expectations of $189.62 million. On average, analysts expect that Afya will post 1.72 EPS for the current year.

About Afya

(Get Free Report)

Afya Limited is a medical education and digital health company focused on Brazil. Through its educational platform, the company provides undergraduate medical education, medical residency preparation, specialization and continuing medical education programs, and other learning resources for students and physicians.

Afya also offers digital products and services intended to support healthcare professionals throughout their careers. These include clinical content, study tools, telemedicine and practice-management solutions, and subscription-based applications designed to assist physicians with education, clinical decision-making, and patient care.

The company has expanded through the development and acquisition of medical schools, education businesses, and health technology platforms serving different stages of the medical professional lifecycle.

Further Reading